PQ-10

PQ-10 is a potent inhibitor of Phosphodiesterase 10A (PDE10A) with IC50 andED50 of 4.6 nM and 13 mg/kg, respectively. PQ-10 induces patterns of brain glucose metabolism which can be a potential translational biomarker. PQ-10 has the potential for researching psychiatric disorders like schizophrenia[1].

Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE)

Research Areas >> Neurological Disease

PDE10A:4.6 nM (IC50)

PQ-10 shows region-specific increases in 2-DG uptake in the globus pallidus (equivalent to the external segment of the globus pallidus in primates) and the lateral habenula in mice[1]. Animal Model: 24 –28 g male C57BL/6 mice, PDE10A WT and KO mice[1] Dosage: 0.16, 0.63, 2.5, and 10 mg/kg Administration: s.c. Result: Showed region-specific increases in 2-DG uptake in the globus pallidus (equivalent to the external segment of the globus pallidus in primates) and the lateral habenula in mice.

[1]. Dedeurwaerdere S, et al. Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: a potential translational biomarker. J Pharmacol Exp Ther. 2011;339(1):210-217.